Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PAO Group","sponsor":"Undiaclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"PAO Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PAOG to Launch Second CBD Nutraceutical Product Later This Week Further Ramping Up 2021 Revenue Potential","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Sleep","graph2":"Approved"},{"orgOrder":0,"company":"PAO Group","sponsor":"CBD pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PAOG Entertains Partnership To Accelerate Development Of CBD Pharmaceutical Treatment For $14 Billion COPD Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by PAO Group

    Menu

    PAO Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PAO Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PAOG Entertains Partnership To Accelerate Development Of CBD Pharmaceutical Treatment For $14 Billion COPD Market

              Details:

              PAOG is considering a partnership opportunity with a larger organization that has the potential to accelerate the ongoing development of RespRx.

              Lead Product(s): Cannabidiol

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RespRx

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: CBD pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership October 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PAO Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PAOG to Launch Second CBD Nutraceutical Product Later This Week Further Ramping Up 2021 Revenue Potential

              Details:

              RelaxRX is available in 30mg Softgels and in an 1800mg Tincture. The CBD oil is 100% derived from full spectrum whole plant hemp oil and contains no added chemicals.

              Lead Product(s): Cannabidiol

              Therapeutic Area: Sleep Product Name: RelaxRX CBD

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PAO Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval

              Details:

              The master services agreement with a clinical research organization in the U.S. will support PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).

              Lead Product(s): Cannabidiol

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RespRx

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undiaclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY